- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Brand Name :
Afinitor, Zortress, Afinitor Disperz
Synonyms :
Everolimus, évérolimus
Class :
Antineoplastics and miscellaneous drugs
Dosage Forms & Strengths
Tablet-Afinitor
2.5mg
5mg
7.5mg
10mg
Tablet for oral suspension
2mg
3mg
5mg
Tablet-Zortress
0.25mg
0.5mg
0.75mg
1mg
10
mg
Orally
once a day
the total duration of therapy is continued until disease progression or no toxicity occurs
Note:
Do not combine the brands of Afinitor tablets and Afinitor Disperz to reach the desired dose
Only use any one of them
10
mg
orally
once a day
the total duration of therapy is continued until disease progression, or no toxicity occurs
Note:
Tablets need to be swallowed with a glass of water but do not chew, crush, or break the tablet
Do not combine the brands of Afinitor tablets and Afinitor Disperz to reach the desired dose
Only use any one of them
10
mg
orally
once a day
the total duration of therapy is continued until disease progression, or no toxicity occurs
Note:
Tablets need to be swallowed with a glass of water but do not chew, crush, or break the tablet
Do not combine the brands of Afinitor tablets and Afinitor Disperz to reach the desired dose
Only use any one of them
10
mg
Orally
once a day
the total duration of therapy is continued until disease progression, or no toxicity occurs
Note:
Tablets need to be swallowed with a glass of water but do not chew, crush, or break the tablet
Do not combine the brands of Afinitor tablets and Afinitor Disperz to reach the desired dose
Only use any one of them
10
mg
Orally
once a day
the total duration of therapy is continued until disease progression, or no toxicity occurs
Note:
Tablets need to be swallowed with a glass of water but do not chew, crush, or break the tablet
Do not combine the brands of Afinitor tablets and Afinitor Disperz to reach the desired dose
Only use any one of them
4.5
mg/m^2
Orally
once a day
the total duration of therapy is continued until disease progression, or no toxicity occurs
Note:
Tablets need to be swallowed with a glass of water but do not chew, crush, or break the tablet
Do not combine the brands of Afinitor tablets and Afinitor Disperz to reach the desired dose
Only use any one of them
Dosage Forms & Strengths
Tablet-Afinitor
2.5mg
5mg
7.5mg
10mg
Tablet for oral suspension
2mg
3mg
5mg
4.5
mg/m^2
Orally
once a day
the total duration of therapy is continued until disease progression, or no toxicity occurs
Note:
Tablets need to be swallowed with a glass of water but do not chew, crush, or break the tablet
Do not combine the brands of Afinitor tablets and Afinitor Disperz to reach the desired dose
Only use any one of them
It may diminish the levels when combined with efavirenz by CYP3A4 metabolism
It may diminish the effect when combined with phenobarbital by affecting the intestinal/hepatic enzyme CYP3A4
It may enhance the effect when combined with miconazole vaginal by affecting CYP3A4 metabolism
nafcillin will decrease the effect of action of everolimus by affecting enzyme CYP3A4 metabolism.
interaction raises immunosuppressive effects and risk of infection
everolimus increases the effect of lapatinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
CYP3A strong enhancers of the small intestine may reduce the bioavailability of everolimus
may inhibit P-glycoprotein (MDR1) efflux transporter by reducing the concentrations and activities
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may enhance the concentration of serum when combined with everolimus
everolimus: they may diminish the serum concentration of CYP3A4 Inducers
everolimus: they may diminish the serum concentration of CYP3A4 Inducers
everolimus: they may diminish the serum concentration of CYP3A4 Inducers
everolimus: they may diminish the serum concentration of CYP3A4 Inducers
everolimus: they may diminish the serum concentration of CYP3A4 Inducers
It may diminish the effects when combined with metformin by pharmacodynamic antagonism
the effect of everolimus is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
fedratinib increases the effect of everolimus by altering the intestinal/ hepatic CYP3A4 enzyme metabolism
It may enhance the risk of adverse reactions when combined with Enzymes
Adverse drug reactions:
Frequency defined
>10%
Anorexia
Asthenia
Anemia
Fatigue
Cough
Diarrhea
Headache
Epistaxis
Pneumonitis
Menstrual irregularities
Nausea
Stomatitis
Constipation
Infections
Edema
Dyspnea
Pyrexia
Vomiting
Rash
1-10%
Congestive heart failure
Dysgeusia
Hypertension
Hemorrhage
Tachycardia
Pregnancy warnings:
Breastfeeding warnings:
Pregnancy Categories:
everolimus:
Everolimus is an anti-cancer medication used to treat breast or renal cancer. It is available in the form of tablets or tablets for suspension.
It is also used during the organ transplantation to suppress the immune system against organ rejection.